Celularity Announces Sales of UltraMIST® Ultrasound Healing Therapy Asset to Sanuwave Health, Inc.

August 19, 2020

Celularity, Inc. (”Celularity” or “the Company”) today announced that it has sold its UltraMIST® Ultrasound Healing Therapy asset to Sanuwave Health, Inc. [OTC PNK: SNWV] (“Sanuwave”) in connection with which Celularity granted Sanuwave certain partnership rights to the Company’s wound care biologic product portfolio. The Company will continue to sell biologic products and other advanced biomaterials on a direct basis outside wound care with a focus around surgical sub-specialties. Celularity manufactures biologic products and other advanced biomaterials at its new, state of the art GMP-ready facility located in Florham Park, NJ. The Company continues to expand its biomaterial portfolio by pairing state-of-the-art manufacturing with the inherent scalability of cell therapies and biomaterials derived from the human placenta.

About Celularity
Celularity, headquartered in Florham Park, N.J., is a next-generation Biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the cells of the post partum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placental-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. In addition, Celularity manufactures and markets two commercial-stage products, Biovance® Human Amniotic Membrane Allograft and Interfyl® Human Connective Tissue Matrix. To learn more, please visit www.celularity.com.

Forward Looking Statements:

This website includes “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements regarding GX Acquisition Corp.’s or GX Acquisition Corp.’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on information available as of the date they were made, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. These risks and uncertainties may be amplified by the COVID- 19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that GX Acquisition Corp. does not know, or that GX Acquisition Corp. currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect GX Acquisition Corp.’s expectations, plans, or forecasts of future events and views as of the date they were made. GX Acquisition Corp. anticipates that subsequent events and developments will cause GX Acquisition Corp.’s assessments to change. Accordingly, forward-looking statements should not be relied upon as representing GX Acquisition Corp.’s views as of any subsequent date, and GX Acquisition Corp. does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Additional risks and uncertainties are identified and discussed in GX Acquisition Corp.’s reports filed with the SEC and available at the SEC’s website at http://www.sec.gov.

No Offer or Solicitation:

The information on this website shall not constitute a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.